Scinai Immunotherapeutics Ltd.’s Post

Prof. Chinmay Ghoroi, PhD recently delivered an insightful talk at the 3rd conference on Nanomechanics for Pharmaceutical Applications (NPA 2023), discussing the critical role of nano-scale contact in processing fine pharmaceutical drug particles. #Nanotechnology #PharmaceuticalEngineering #NPA2023

Did you know that Charged Aerosol Detection (CAD) is nearly 20 years old!!! 🤯 🔬Over those years, the technique has been developed and is now heavily relied upon in most, if not all, pharmaceutical and biopharma labs! 💊One particular example is Amgen, who use the CAD for quantitative assays across early and late-stage pharmaceutical drug development. 📅This Thursday (4th April), Amgen will be sharing examples of how they’ve successfully developed new methods, transferred traditional LC-UV methods, and implemented an LC-MS-CAD setup to really expand their capabilities So the question is… -      Do you want to expand your capabilities in your lab ❓ -      Struggling with the analysis of new and upcoming compounds/therapeutics❓ -      Need a solution that fits in with your current laboratory setup (instruments and/or CDS) -      Unsure what CAD is or how it could improve your lab’s capabilities ❓ If you answered yes to any of those, which I'm sure you have, then this is one webinar you can’t miss!!! So sign up now 📎https://lnkd.in/d_ad4ebW

Pharma Commercialization: A Deep Dive in Market Access The increasing complexity of novel therapeutics has created a tailwind for pharmaceutical research and development spend, buoying the number of novel drug approvals and increasing the demand for sophisticated, outsourced commercialization capabilities. In this white paper, we take an in-depth look at market access in the United States, one of the most sought-after subsegments of pharma commercialization. Click here to read the report: https://lnkd.in/eSjK_6Em

Over the last 20 years, pharmaceutical laboratories have faced persistent regulatory pressure to adopt paperless operations. This push towards digitalization aligns with the industry's business needs and objectives to elevate overall lab efficiency. A highly efficient laboratory is characterized by its ability to achieve the shortest possible turnaround time while maintaining uncompromising quality in analytical results. Also, it operates as a cost-effective business, optimizing resource utilization, and productivity. In this study, a small-scale analytical laboratory was configured to emulate a biopharmaceutical quality control (QC) lab for monoclonal antibody (mAb) release tests. The primary aim of this study is to showcase a streamlined mAb QC analytical workflow from sample submission to final answers in the OpenLab CDS and SLIMS ecosystem. Read more: https://lnkd.in/dKsChCBY

This week, we are kicking off our first March tradeshow in 2024! Biologics 2024 is around the corner, and our team members Tim Nieters and Andrew Kennedy will be on site at booth #53 to answer any questions for your peptide and oligonucleotide projects. As a sponsor for Biologics 2024, we are a leader in GMP manufacturing and comprehensive CRDMO services for synthetic peptide and oligonucleotide production. With over two decades of dedicated service to the pharmaceutical industry, CPC Scientific has emerged as a trusted provider of high-quality products, supporting researchers and companies globally. CPC Scientific's legacy includes hundreds of projects in clinical development and 10 successful commercial projects worldwide. Notably, in the upcoming year, CPC Scientific is set to enhance the pharmaceutical supply chain's resilience in the United States with the opening of our California GMP facility, ensuring the secure availability of critical therapeutic APIs. View the full agenda: https://hubs.la/Q02ljQtL0 #Biologics24 #OGBiologics #CPCScientific #GMPManufacturing #CRDMO #PharmaceuticalIndustry #TherapeuticDevelopment #Innovation

“It always seems impossible until it’s done.” —Nelson Mandela We can support your company with our expertise on pharmaceutical, biotechnology or medical device clinical studies. Let's do it together! GCP-Service International   #cro #clinicalresearch #clinicaltrials #clinicalstudies #pharmaceuticals #medicaldevices #invitrodiagnostics #biotechnology

The European Union In Vitro Diagnostics Regulation (IVDR) is changing the landscape of diagnostic provision within the EU, but what are the implications to both diagnostic providers and the pharmaceutical industry as a whole? Our latest blog post with Almac Group dives into this new regulation, it's background, challenges & what you need to know going forward. https://lnkd.in/gfkkgg2V

Check out our latest blog on Scientist.Com

Early clinical strategy refers to the comprehensive plan and approach that pharmaceutical companies, biotech firms, and researchers develop for the initial phases of clinical development of a new drug. These early phases, typically known as Phase 1 and Phase 2 clinical trials, aim to assess the safety, tolerability, and preliminary efficacy of the investigational product […]